35.1 Acute Flares of Inflammatory Bowel Disease

Epidemiology, Pathophysiology & Phenotypic Differentiation: UC vs. Crohn Disease

Inflammatory bowel disease (IBD) encompasses two primary chronic idiopathic inflammatory conditions of the gastrointestinal tract: Ulcerative Colitis (UC) and Crohn Disease (CD). In the United States, IBD affects approximately 1.6 to 3.1 million individuals, with peak bimodal incidence occurring between 15 to 30 years of age and a secondary, smaller peak between 50 to 70 years. While both disorders result from an inappropriate immune response to commensal enteric microflora in genetically susceptible hosts, their anatomical distribution, depth of tissue injury, endoscopic findings, histopathology, and clinical course diverge fundamentally.

Clinical and Pathologic Comparison: UC vs. CD

---

Environmental Modifiers & Provocative Triggers of Acute Flares

IBD is characterized by unpredictable cycles of clinical remission punctuated by acute inflammatory flares. Identifying and rapidly correcting modifiable exogenous triggers is vital in primary care practice:

1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs):

   • Both non-selective NSAIDs (ibuprofen, naproxen, ketorolac) and selective COX-2 inhibitors inhibit gastroprotective prostaglandin E2 (PGE2) synthesis within the colonic mucosa.
   • Loss of mucosal prostaglandins impairs mucosal microvascular blood flow, increases intestinal epithelial permeability, facilitates bacterial translocation, and precipitates acute clinical relapse in up to 20% to 30% of patients within 1 to 2 weeks of initiation.
   • Clinical Mandate: Acetaminophen (up to 2-3 g/day) should be utilized for analgesia and antipyresis; NSAIDs should be strictly avoided.

2. Superimposed Enteric Infections:

   • Clostridioides difficile Infection (CDI): IBD patients have a 3- to 8-fold increased susceptibility to C. difficile, even in the absence of recent antibiotic exposure or hospitalization. CDI mimics an idiopathic flare, accelerates clinical deterioration, and quadruples mortality if unrecognized. Every patient presenting with an acute IBD flare must undergo stool testing for C. difficile GDH antigen and Toxin A/B EIA with reflex NAAT.
   • Cytomegalovirus (CMV) Colitis: CMV reactivation within granulation tissue is a frequent cause of acute flare refractory to intravenous corticosteroid therapy. In patients hospitalized with severe steroid-refractory colitis, flexible sigmoidoscopy with mucosal biopsy must evaluate for intranuclear inclusion bodies ("owl's eye" inclusions) and CMV immunohistochemistry; confirmed cases require intravenous ganciclovir (5 mg/kg IV every 12 hours).
   • Common bacterial pathogens (Campylobacter, Salmonella, Shigella, E. coli O157:H7) must also be excluded via multiplex stool PCR or stool culture.

3. The Smoking Paradox:

   • Crohn Disease: Tobacco smoking is a potent deleterious modifier. Active cigarette smoking doubles the risk of developing CD, triples the rate of clinical flares, accelerates stricture and fistula formation, increases the need for immunosuppressive therapy, and significantly raises the rate of postoperative surgical recurrence. Complete smoking cessation is mandatory.
   • Ulcerative Colitis: Cigarette smoking displays an enigmatic, paradoxical protective association. Current smokers have a lower incidence of UC and a milder clinical course. Crucially, smoking cessation frequently precipitates severe, new-onset UC flares or triggers the initial clinical presentation within the first 1 to 3 years following tobacco discontinuation. Nicotine stimulates colonic mucin secretion and alters mucosal helper T-cell profiles; however, resumption of smoking is never recommended therapeutically due to cardiovascular and oncologic hazards.

4. Medication Non-Adherence & Underdosing:

   • Premature discontinuation of maintenance 5-aminosalicylate (5-ASA) or biologic therapy (due to cost, pill burden, or symptom resolution) is responsible for over 40% of outpatient flares.
   • In patients receiving biologic agents (e.g., infliximab, adalimumab), secondary loss of response commonly occurs due to the development of neutralizing anti-drug antibodies (ADAs) and subtherapeutic serum trough drug concentrations.

---

Biomarkers of Active Inflammation & Diagnostic Triage

Objective biomarkers are essential in ambulatory family medicine to distinguish active inflammatory flares from non-inflammatory functional gastrointestinal symptoms (e.g., overlapping irritable bowel syndrome, small intestinal bacterial overgrowth, or bile acid diarrhea) and to guide treatment intensification without requiring immediate invasive colonoscopy.

                      OBJECTIVE BIOMARKER TRIAGE IN IBD

              Patient with Known IBD Presents with Diarrhea & Cramps
                                      │
               ┌──────────────────────┴──────────────────────┐
               ▼                                             ▼
       Systemic Inflammatory                         Fecal Neutrophilic
             Biomarkers                                  Biomarkers
  • CRP (>5-10 mg/L = active systemic)       • Fecal Calprotectin (>150-250 mcg/g)
  • ESR (>30 mm/h in severe UC)              • Fecal Lactoferrin (elevated)
  • CBC (anemia, thrombocytosis >450k)       • Rules OUT functional symptoms (IBS)
  • Albumin (<3.0 g/dL = severe disease)     • High correlation with mucosal ulceration
               │                                             │
               └──────────────────────┬──────────────────────┘
                                      ▼
                      Exclude Superimposed Infection
                      • Stool C. diff GDH / Toxin PCR
                      • Multiplex GI Pathogen NAAT
                                      │
                                      ▼
                     Stratify Truelove & Witts Severity
                     • Mild/Moderate: Outpatient 5-ASA / Corticosteroids
                     • Severe: Urgent Hospital Admission & IV Steroids

Non-Invasive Stool Biomarkers

• Fecal Calprotectin: A 36-kDa calcium- and zinc-binding protein derived predominantly from the cytosol of degranulating mucosal neutrophils. It is extremely stable in stool at room temperature for up to 7 days.
  • Values <50 mcg/g: Highly sensitive (>95%) for the absence of significant mucosal inflammation; strongly points toward functional bowel symptoms (irritable bowel syndrome) rather than an active IBD flare.
  • Values 50 to 150 mcg/g: Borderline zone; represents low-grade inflammation or resolving flare.
  • Values >150 to 250 mcg/g: Highly specific (>85-90%) for active mucosal endoscopic inflammation, crypt abscesses, and mucosal ulceration. Serial measurements serve as a surrogate marker for endoscopic mucosal healing.
• Fecal Lactoferrin: An iron-binding glycoprotein contained within the secondary granules of polymorphonuclear neutrophils. Reflects acute mucosal leukocyte infiltration and parallels calprotectin performance.

Systemic Serum Biomarkers

• C-Reactive Protein (CRP): Acute-phase reactant synthesized by hepatocytes under IL-6 stimulation. Rises briskly in active Crohn disease (which exhibits a strong transmural systemic cytokine surge), but may remain normal or only mildly elevated in up to 30% to 50% of patients with active, mild-to-moderate ulcerative colitis restricted to the rectum or left colon.
• Erythrocyte Sedimentation Rate (ESR): Reflects elevated fibrinogen; incorporated into the classic Truelove and Witts criteria for UC severity.
• Complete Blood Count (CBC):
  • Platelets: Thrombocytosis (>450,000/mcL) is a sensitive acute-phase marker reflecting active mucosal ulceration.
  • Hemoglobin/Hematocrit: Microcytic hypochromic anemia (chronic gastrointestinal blood loss and iron deficiency) combined with normocytic anemia of chronic disease.
• Serum Albumin: Marked hypoalbuminemia (<3.0 g/dL) results from mucosal exudative protein loss ("protein-losing enteropathy") and cytokine-mediated suppression of hepatic synthesis; it serves as a powerful negative prognostic indicator predicting failure of medical therapy and heightened colectomy risk.

---

Truelove and Witts Criteria for Ulcerative Colitis Flare Severity

In ambulatory and urgent care settings, the validated Truelove and Witts criteria remain the clinical gold standard for risk-stratifying acute flares of ulcerative colitis and determining the immediate level of care:

Truelove and Witts Severity Classification Table

Diagnostic Decision Rule: Severe colitis requires ≥6 bloody bowel movements daily PLUS at least ONE of the four systemic toxicity criteria (fever, tachycardia, anemia, or elevated ESR/CRP). The presence of fulminant colitis or localized peritonitis signals impending perforation or toxic megacolon and mandates emergency inpatient surgical and medical care.

---

Outpatient Medical Management of Mild-to-Moderate Flares

Outpatient management focuses on rapid induction of mucosal remission while transitioning or optimizing a maintenance therapeutic regimen.

1. Ulcerative Colitis: Topical & Oral 5-ASA Optimization

• Ulcerative Proctitis (Disease limited to distal 15 cm from anal verge):
  • First-Line Induction: Mesalamine rectal suppository 1,000 mg (1 g) once daily at bedtime.
  • Pharmacokinetic Pearl: Suppositories melt at body temperature and disperse active mesalamine directly into the rectal vault up to the rectosigmoid junction (15-20 cm). Clinical trial evidence proves topical rectal mesalamine is significantly superior to oral mesalamine and superior to topical rectal corticosteroids for proctitis.
• Left-Sided Colitis (Disease extending from rectum to splenic flexure):
  • First-Line Induction: Mesalamine rectal enema 4 g once daily at bedtime PLUS Oral Mesalamine 2.4 to 4.8 g per day.
  • Pharmacokinetic Pearl: Liquid enemas have a delivery volume of 60 mL, which readily refluxes retrogradely throughout the descending colon up to the splenic flexure. Combined topical and oral 5-ASA therapy yields significantly higher clinical and endoscopic remission rates than either agent alone.
• Extensive Colitis / Pancolitis (Extending proximal to the splenic flexure):
  • Oral Mesalamine 2.4 to 4.8 g once daily (or split dosing) combined with bedtime mesalamine enemas for rapid relief of distal tenesmus and rectal bleeding.
  • Alternative: Sulfasalazine 3 to 4 g/day in divided doses (requires concurrent oral folic acid 1 mg daily, as sulfasalazine competitively inhibits intestinal folate conjugate absorption).

2. Mild-to-Moderate Flares Refractory to 5-ASA: Oral Corticosteroid Induction

When patients fail to achieve clinical improvement on maximized 5-ASA within 2 to 4 weeks, or present with moderate flare severity:

• Oral Budesonide MMX (Multi-Matrix System, 9 mg once daily in the morning for 8 weeks):
  • Specially formulated for ulcerative colitis; releases budesonide throughout the entire colon. Exhibits >90% hepatic first-pass metabolism via cytochrome P450 3A4, delivering high local anti-inflammatory activity while minimizing systemic glucocorticoid toxicities.
• Oral Controlled-Ileal-Release Budesonide (Entocort EC, 9 mg once daily for 8 weeks, followed by a 2-4 week taper):
  • First-Line Induction for Mild-to-Moderate Ileocecal Crohn Disease (involving the terminal ileum and/or ascending colon).
  • Formulated with an enteric ethylcellulose coating that dissolves at pH >5.5 (ileocecal junction), achieving high target tissue concentrations with minimal systemic absorption.
  • Clinical Distinction: Controlled-release budesonide is ineffective for extensive colonic Crohn's or left-sided colitis because the drug is released exclusively in the ileum and right colon.
• Oral Systemic Prednisone (40 to 60 mg orally once daily for 1 to 2 weeks, followed by a structured taper of 5-10 mg weekly over 8 to 12 weeks):
  • Indicated for moderate-to-severe UC or CD flares that do not respond to topical therapy or budesonide.

  • [!IMPORTANT]

  • STRICT GUIDELINE RULE: Systemic corticosteroids are effective ONLY for acute induction of remission; they are COMPLETELY INEFFECTIVE and STRICTLY CONTRAINDICATED for maintenance therapy due to failure to achieve mucosal healing, high relapse rates, and severe long-term morbidities (osteoporosis, avascular necrosis, cataracts, opportunistic infections, adrenal suppression, impaired wound healing).

---

Hospitalization Criteria & Inpatient Management of Severe / Fulminant Colitis

Any patient fulfilling Truelove and Witts severe or fulminant criteria, or demonstrating hemodynamic instability, peritoneal irritation, severe intractable dehydration, failure of outpatient oral corticosteroids after 5 to 7 days, or severe malnutrition, requires immediate hospital admission.

Standard Inpatient Severe Colitis Protocol

1. Intravenous Corticosteroid Therapy:
   • Methylprednisolone 60 mg IV once daily (or Hydrocortisone 100 mg IV every 8 hours).
   • Doses higher than 60 mg/day of methylprednisolone provide no additional therapeutic benefit and dramatically increase adverse events.
2. Chemical Venous Thromboembolism (VTE) Prophylaxis:

   • [!CAUTION]

   • CRITICAL EXAM PEARL: VTE PROPHYLAXIS IN ACTIVE IBD BLEEDING
   • Patients hospitalized with active IBD flares have a 3- to 8-fold increased risk of deep vein thrombosis (DVT) and fatal pulmonary embolism (PE) driven by cytokine-mediated hypercoagulability, thrombocytosis, and elevated fibrinogen.
   • Active rectal bleeding / hematochezia is NOT a contraindication to chemical VTE prophylaxis! All hospitalized IBD patients must receive prophylactic anticoagulation with low-molecular-weight heparin (enoxaparin 40 mg SQ daily) or low-dose unfractionated heparin (5,000 units SQ every 8-12 hours), unless there is massive, hemodynamically destabilizing life-threatening hemorrhage.
3. Bowel Rest & Nutrition:
   • Bowel rest (NPO with IV isotonic fluids) is reserved for severe toxic patients or impending surgery. Enteral nutrition is preferred over total parenteral nutrition (TPN) whenever tolerated.
4. Early Surgical Consultation:
   • An experienced colorectal surgical team must be involved on Day 1 of admission to co-manage the patient and prepare for potential emergency subtotal colectomy.
5. Day 3 to Day 5 Decision Point: Oxford Criteria & Rescue Therapy:
   • Clinical response to IV steroids must be rigorously evaluated on Day 3 using the validated Oxford Criteria:
     • If on Day 3 of IV steroids, the patient has >8 bowel movements per day, OR 3 to 8 bowel movements per day with a serum CRP >45 mg/L, the risk of failing medical therapy and requiring emergent colectomy exceeds 85%.
   • Rescue Medical Therapy: Do not continue ineffective steroids indefinitely. Initiate rescue therapy with:
     • Infliximab (anti-TNF alpha): 5 to 10 mg/kg IV infusion at weeks 0, 2, and 6 (often accelerated dosing for severe hypoalbuminemic colitis); OR
     • Cyclosporine IV: Continuous infusion of 2 mg/kg/day targeting whole blood trough levels of 150 to 250 ng/mL.
   • If the patient does not achieve clear, substantial clinical improvement within 48 to 72 hours of rescue therapy, emergency subtotal colectomy with end ileostomy is life-saving.

---

Toxic Megacolon: Pathophysiology, Clinical Criteria & Emergency Care

Toxic megacolon is a catastrophic, potentially lethal complication of severe colitis occurring in 1% to 5% of IBD patients (most frequently in ulcerative colitis, but also seen in Crohn's colitis, C. difficile pseudomembranous colitis, and ischemic colitis).

Pathophysiology

Inflammation extends through the submucosa into the circular and longitudinal smooth muscle layers of the muscularis propria (transmural necrosis). Degranulating neutrophils and macrophages release massive amounts of inflammatory cytokines and inducible nitric oxide synthase (iNOS). High concentrations of nitric oxide paralyze colonic smooth muscle myocytes, abolishing basal motor tone and peristalsis. The colonic lumen rapidly dilates with gas and liquid feces. The colonic wall thins to paper-thin caliber, predisposing to microperforation, gross transmural perforation, fecal peritonitis, and septic shock.

Diagnostic Criteria (Jalan / Truelove Criteria)

Diagnosis requires radiographic evidence of non-obstructive colonic dilation combined with systemic toxicity:

                     DIAGNOSTIC CRITERIA FOR TOXIC MEGACOLON

  1. Radiographic Criterion: Colonic distension >6 cm (most prominent in
     the transverse colon on supine abdominal radiograph / CT)
                                    +
  2. At least THREE of the following systemic inflammatory features:
     • Fever >38.6°C (101.5°F)
     • Heart rate >120 beats per minute
     • Leukocytosis >10,500 cells/mcL (or >10% immature band forms)
     • Anemia (Hemoglobin <10.5 g/dL)
                                    +
  3. At least ONE of the following clinical toxicity signs:
     • Dehydration / hypovolemia
     • Altered mental status / acute confusion
     • Electrolyte disturbances (hypokalemia, hypomagnesemia)
     • Systemic hypotension / septic shock

Iatrogenic Precipitating Factors & Absolute Contraindications

[!WARNING] STRICT SAFETY CONTRAINDICATIONS IN SEVERE COLITIS & MEGACOLON Toxic megacolon is frequently precipitated by medications or procedures that paralyze colonic motility or increase luminal wall tension:

1. Antimotility Agents & Opioids: Loperamide, diphenoxylate-atropine, morphine, oxycodone, and hydromorphone.
2. Anticholinergic Agents: Dicyclomine, hyoscyamine, oxybutynin, and tricyclic antidepressants.
3. Diagnostic Colonoscopy & Barium Enema: Full optical colonoscopy and contrast barium enemas are STRICTLY CONTRAINDICATED! Mechanical air insufflation, colonoscope insertion, and barium hydrostatic pressure dramatically accelerate wall tension, triggering immediate colonic perforation and catastrophic fecal peritonitis. If mucosal evaluation is mandatory, perform only a gentle, unprepared flexible sigmoidoscopy with minimal air/CO2 insufflation.

Emergency Management Protocol

1. Immediate Medical Resuscitation:
   • Complete bowel rest (strict NPO).
   • Placement of a nasogastric (NG) tube for gastric decompression.
   • Aggressive intravenous isotonic crystalloid fluid resuscitation to restore intravascular volume.
   • Aggressive correction of electrolyte abnormalities (especially hypokalemia and hypomagnesemia, which directly impair colonic muscular contraction).
   • Frequent patient repositioning: The "roll-over maneuver" (turning the patient from supine to prone or knee-chest position for 15 minutes every 2 hours) allows buoyant gas trapped in the anterior transverse colon to migrate retrogradely into the rectum, facilitating decompression.
2. Pharmacotherapy:
   • Intravenous Methylprednisolone 60 mg daily.
   • Broad-Spectrum Intravenous Antibiotics: To cover enteric Gram-negative bacilli and anaerobes translocating across the compromised, necrotic colonic mucosa (e.g., Ceftriaxone 2 g IV daily PLUS Metronidazole 500 mg IV every 8 hours, or Piperacillin-Tazobactam 3.375-4.5 g IV every 6 hours).
3. Serial Surveillance & Emergency Surgical Indications:
   • Serial abdominal plain radiographs (supine KUB) and physical examinations every 12 hours.
   • Immediate Emergency Surgery (Subtotal Colectomy with End Ileostomy) is indicated for:
     • Free intra-abdominal air (perforation);
     • Worsening localized or generalized peritonitis;
     • Hemodynamic collapse / progressive septic shock; OR
     • Failure of maximal medical therapy to decrease colonic caliber within 24 to 72 hours.

Colorectal Cancer (CRC) Surveillance Protocols in IBD

Patients with long-standing inflammatory bowel disease involving the colon face a substantially elevated risk of developing colorectal adenocarcinoma. Unlike sporadic CRC, which arises via the traditional adenoma-to-carcinoma sequence (initiating with APC mutation and progressing to KRAS and p53 over 10-15 years), colitis-associated colorectal cancer arises via the chronic inflammation-dysplasia-carcinoma pathway. In this setting, loss of p53 occurs early in non-dysplastic or inflamed mucosa, leading to multifocal, flat, non-polypoid dysplastic lesions that are notoriously difficult to detect.

Colorectal Cancer Surveillance Guidelines Table

Surveillance Modalities & Endoscopic Technique

• High-Definition Chromoendoscopy: Involves spraying topical dye (indigo carmine or methylene blue) or using digital virtual chromoendoscopy (narrow-band imaging [NBI]) to highlight mucosal pit patterns and identify flat, subtle dysplastic lesions. Targeted biopsies are taken of all suspicious mucosal irregularities.
• Standard White-Light Colonoscopy: If chromoendoscopy is unavailable, random 4-quadrant mucosal biopsies must be obtained every 10 cm throughout the entire colon, yielding a minimum of 32 to 33 biopsies to provide acceptable statistical sensitivity.
• Management of Dysplasia:
  • Visible, circumscribed polypoid dysplasia: If the lesion can be completely resected endoscopically and surrounding mucosal biopsies are free of dysplasia, close endoscopic surveillance is acceptable.
  • Invisible dysplasia (detected on random biopsy) or multifocal high-grade dysplasia: Mandates total proctocolectomy with ileal pouch-anal anastomosis (IPAA) due to an exceptionally high risk of synchronous invasive adenocarcinoma (>40-50%).